519 related articles for article (PubMed ID: 33909009)
21. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters.
Trimpert J; Herwig S; Stein J; Vladimirova D; Adler JM; Abdelgawad A; Firsching TC; Thoma T; Sehouli J; Osterrieder K; Gruber AD; Sawitzki B; Sander LE; Cichon G
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835096
[TBL] [Abstract][Full Text] [Related]
22. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
23. Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.
Le Gars M; Sadoff J; Struyf F; Heerwegh D; Truyers C; Hendriks J; Gray G; Grinsztejn B; Goepfert PA; Schuitemaker H; Douoguih M
J Infect Dis; 2022 Sep; 226(6):979-982. PubMed ID: 35429381
[TBL] [Abstract][Full Text] [Related]
24. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
25. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
[TBL] [Abstract][Full Text] [Related]
26. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Vogel AB; Kanevsky I; Che Y; Swanson KA; Muik A; Vormehr M; Kranz LM; Walzer KC; Hein S; Güler A; Loschko J; Maddur MS; Ota-Setlik A; Tompkins K; Cole J; Lui BG; Ziegenhals T; Plaschke A; Eisel D; Dany SC; Fesser S; Erbar S; Bates F; Schneider D; Jesionek B; Sänger B; Wallisch AK; Feuchter Y; Junginger H; Krumm SA; Heinen AP; Adams-Quack P; Schlereth J; Schille S; Kröner C; de la Caridad Güimil Garcia R; Hiller T; Fischer L; Sellers RS; Choudhary S; Gonzalez O; Vascotto F; Gutman MR; Fontenot JA; Hall-Ursone S; Brasky K; Griffor MC; Han S; Su AAH; Lees JA; Nedoma NL; Mashalidis EH; Sahasrabudhe PV; Tan CY; Pavliakova D; Singh G; Fontes-Garfias C; Pride M; Scully IL; Ciolino T; Obregon J; Gazi M; Carrion R; Alfson KJ; Kalina WV; Kaushal D; Shi PY; Klamp T; Rosenbaum C; Kuhn AN; Türeci Ö; Dormitzer PR; Jansen KU; Sahin U
Nature; 2021 Apr; 592(7853):283-289. PubMed ID: 33524990
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
[TBL] [Abstract][Full Text] [Related]
28. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
Darling TL; Ying B; Whitener B; VanBlargan LA; Bricker TL; Liang CY; Joshi A; Bamunuarachchi G; Seehra K; Schmitz AJ; Halfmann PJ; Kawaoka Y; Elbashir SM; Edwards DK; Thackray LB; Diamond MS; Boon ACM
Med; 2022 May; 3(5):309-324.e6. PubMed ID: 35584653
[TBL] [Abstract][Full Text] [Related]
29. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
Gorman MJ; Patel N; Guebre-Xabier M; Zhu AL; Atyeo C; Pullen KM; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yuan D; Bowman KA; Zhou B; Maciejewski S; McGrath ME; Logue J; Frieman MB; Montefiori D; Mann C; Schendel S; Amanat F; Krammer F; Saphire EO; Lauffenburger DA; Greene AM; Portnoff AD; Massare MJ; Ellingsworth L; Glenn G; Smith G; Alter G
Cell Rep Med; 2021 Sep; 2(9):100405. PubMed ID: 34485950
[TBL] [Abstract][Full Text] [Related]
30. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
[TBL] [Abstract][Full Text] [Related]
31. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
32. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
PLoS Pathog; 2023 Nov; 19(11):e1011772. PubMed ID: 37943890
[TBL] [Abstract][Full Text] [Related]
33. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN.
Yu J; Thomas PV; McMahan K; Jacob-Dolan C; Liu J; He X; Hope D; Martinez EJ; Chen WH; Sciacca M; Hachmann NP; Lifton M; Miller J; Powers OC; Hall K; Wu C; Barrett J; Swafford I; Currier JR; King J; Corbitt C; Chang WC; Golub E; Rees PA; Peterson CE; Hajduczki A; Hussin E; Lange C; Gong H; Matyas GR; Rao M; Paquin-Proulx D; Gromowski GD; Lewis MG; Andersen H; Davis-Gardner M; Suthar MS; Michael NL; Bolton DL; Joyce MG; Modjarrad K; Barouch DH
Sci Adv; 2022 Nov; 8(47):eade4433. PubMed ID: 36417525
[TBL] [Abstract][Full Text] [Related]
34. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
Harrington P; Doores KJ; Radia D; O'Reilly A; Lam HPJ; Seow J; Graham C; Lechmere T; McLornan D; Dillon R; Shanmugharaj Y; Espehana A; Woodley C; Saunders J; Curto-Garcia N; O'Sullivan J; Raj K; Kordasti S; Malim MH; Harrison C; de Lavallade H
Br J Haematol; 2021 Sep; 194(6):999-1006. PubMed ID: 34085278
[TBL] [Abstract][Full Text] [Related]
35. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
Naranbhai V; St Denis KJ; Lam EC; Ofoman O; Garcia-Beltran WF; Mairena CB; Bhan AK; Gainor JF; Balazs AB; Iafrate AJ;
Cancer Cell; 2022 Jan; 40(1):103-108.e2. PubMed ID: 34990570
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COV2.S Vaccination in Non-Human Primates.
Dari A; Solforosi L; Roozendaal R; Hoetelmans RMW; Pérez-Ruixo JJ; Boulton M
J Pharmacol Exp Ther; 2023 Oct; 387(1):121-130. PubMed ID: 37536955
[TBL] [Abstract][Full Text] [Related]
37. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
Corbett KS; Flynn B; Foulds KE; Francica JR; Boyoglu-Barnum S; Werner AP; Flach B; O'Connell S; Bock KW; Minai M; Nagata BM; Andersen H; Martinez DR; Noe AT; Douek N; Donaldson MM; Nji NN; Alvarado GS; Edwards DK; Flebbe DR; Lamb E; Doria-Rose NA; Lin BC; Louder MK; O'Dell S; Schmidt SD; Phung E; Chang LA; Yap C; Todd JM; Pessaint L; Van Ry A; Browne S; Greenhouse J; Putman-Taylor T; Strasbaugh A; Campbell TA; Cook A; Dodson A; Steingrebe K; Shi W; Zhang Y; Abiona OM; Wang L; Pegu A; Yang ES; Leung K; Zhou T; Teng IT; Widge A; Gordon I; Novik L; Gillespie RA; Loomis RJ; Moliva JI; Stewart-Jones G; Himansu S; Kong WP; Nason MC; Morabito KM; Ruckwardt TJ; Ledgerwood JE; Gaudinski MR; Kwong PD; Mascola JR; Carfi A; Lewis MG; Baric RS; McDermott A; Moore IN; Sullivan NJ; Roederer M; Seder RA; Graham BS
N Engl J Med; 2020 Oct; 383(16):1544-1555. PubMed ID: 32722908
[TBL] [Abstract][Full Text] [Related]
39. Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques.
Yu J; Thomas PV; Sciacca M; Wu C; Liu J; He X; Miller J; Hachmann NP; Surve N; McMahan K; Jacob-Dolan C; Powers O; Hall K; Barrett J; Hope D; Mazurek CR; Murdza T; Chang WC; Golub E; Rees PA; Peterson CE; Hajduczki A; Chen WH; Martinez EJ; Hussin E; Lange C; Gong H; Matyas GR; Rao M; Suthar M; Boursiquot M; Cook A; Pessaint L; Lewis MG; Andersen H; Bolton DL; Michael NL; Joyce MG; Modjarrad K; Barouch DH
Cell Rep Med; 2023 Apr; 4(4):101018. PubMed ID: 37023746
[TBL] [Abstract][Full Text] [Related]
40. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
